Caroline Arber

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


56 publications

2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2000 |
 
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT.
Novak U., Mooyaart J.E., Daskalakis M., Scheid C., Gabellier L., Yakoub-Agha I., Ram R., Forcade E., López-Corral L., Nicholson E. et al., 2024/11. Bone marrow transplantation, 59 (11) pp. 1631-1634. Peer-reviewed.
Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.
Arber C., Baerlocher G., Chalandon Y., Daskalakis M., Duchosal M., Fehr M., Gerull S., Güngör T., Nair G., Pabst T. et al., 2024/10/03. Swiss medical weekly, 154 p. 3704. Peer-reviewed.
 
Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins.
Petruzzella A., Bruand M., Santamaria-Martínez A., Katanayeva N., Reymond L., Wehrle S., Georgeon S., Inel D., van Dalen F.J., Viertl D. et al., 2024/09. Nature chemical biology, 20 (9) pp. 1188-1198. Peer-reviewed.
Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.
Spertini C., Bénéchet A.P., Birch F., Bellotti A., Román-Trufero M., Arber C., Auner H.W., Mitchell R.A., Spertini O., Smirnova T., 2024/03/28. Cell death discovery, 10 (1) p. 157. Peer-reviewed.
 
Two to tango: engineered T cells against AML.
Arber C., 2024/02/08. Blood, 143 (6) pp. 476-478. Peer-reviewed.
 
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg J.R., Baldomero H., Ansari M., Arber C., Chalandon Y., Daskalakis M., Diepold M., Diesch-Furlanetto T., Duchosal M.A., Gerull S. et al., 2024/01. Hematological oncology, 42 (1) pp. e3241. Peer-reviewed.
 
Reductive carboxylation epigenetically instructs T cell differentiation.
Jaccard A., Wyss T., Maldonado-Pérez N., Rath J.A., Bevilacqua A., Peng J.J., Lepez A., Von Gunten C., Franco F., Kao K.C. et al., 2023/09. Nature, 621 (7980) pp. 849-856. Peer-reviewed.
 
Développements récents en hématologie, Partie 2
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/23. Forum Médical Suisse ‒ Swiss Medical Forum.
 
Développements récents en hématologie, Teil 1
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/16. Forum Médical Suisse ‒ Swiss Medical Forum.
Computational design of dynamic receptor-peptide signaling complexes applied to chemotaxis.
Jefferson R.E., Oggier A., Füglistaler A., Camviel N., Hijazi M., Villarreal A.R., Arber C., Barth P., 2023/05/19. Nature communications, 14 (1) p. 2875. Peer-reviewed.
Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
Camviel Nicolas, Wolf Benita, Croce Giancarlo, Gfeller David, Zoete Vincent, Arber Caroline, 2022/11. Journal for ImmunoTherapy of Cancer, 10 (11) pp. e005091. Peer-reviewed.
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
Stadelmann Raphael, Cairoli Anne, Arber Caroline, 2022/10/31. healthbook TIMES Oncology Hematology - Edition 3 / 2022 13. Peer-reviewed.
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.
Omer B., Cardenas M.G., Pfeiffer T., Daum R., Huynh M., Sharma S., Nouraee N., Xie C., Tat C., Perconti S. et al., 2022/04/01. Cancer immunology research, 10 (4) pp. 512-524. Peer-reviewed.
 
Rapid BCMA downmodulation on myeloma cells upon CAR T cell contact is mediated by trogocytosis and BCMA internalization
Camviel Nicolas, Wolf Benita, Croce Giancarlo, Gfeller David, Zoete Vincent, Arber Caroline, 2022..
Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia.
Bajwa G., Arber C., 2022. Frontiers in immunology, 13 p. 830021. Peer-reviewed.
Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells.
Bajwa G., Lanz I., Cardenas M., Brenner M.K., Arber C., 2020/11. Journal for immunotherapy of cancer, 8 (2) pp. e001487. Peer-reviewed.
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4<sup>+</sup> T cells.
Rath J.A., Bajwa G., Carreres B., Hoyer E., Gruber I., Martínez-Paniagua M.A., Yu Y.R., Nouraee N., Sadeghi F., Wu M. et al., 2020/07. Science advances, 6 (27) pp. eaaz7809. Peer-reviewed.
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath J.A., Arber C., 2020/06/18. Cells, 9 (6) p. 1485. Peer-reviewed.
Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C., Gruber I., Arber C., 2020. Frontiers in immunology, 11 p. 583716. Peer-reviewed.
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
Wolf B., Zimmermann S., Arber C., Irving M., Trueb L., Coukos G., 2019/02. Drug safety, 42 (2) pp. 315-334. Peer-reviewed.
 
Progrès récents et orientations futures de la thérapie avec cellules CAR-T en oncologie pédiatrique [Recent advances and future directions in CAR-T cell therapy in pediatric oncology]
Ceppi F., Renella R., Diezi M., Ansari M., Duchosal M.A., Arber C., Kandalaft L., Coukos G., Beck-Popovic M., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 85-91. Peer-reviewed.
 
Computational design of orthogonal membrane receptor-effector switches for rewiring signaling pathways.
Young M., Dahoun T., Sokrat B., Arber C., Chen K.M., Bouvier M., Barth P., 2018/07/03. Proceedings of the National Academy of Sciences of the United States of America, 115 (27) pp. 7051-7056. Peer-reviewed.
 
c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals.
Nishimura C.D., Brenner D.A., Mukherjee M., Hirsch R.A., Ott L., Wu M.F., Liu H., Dakhova O., Orange J.S., Brenner M.K. et al., 2017/12/21. Blood, 130 (25) pp. 2739-2749. Peer-reviewed.
 
Reprogramming cellular functions with engineered membrane proteins.
Arber C., Young M., Barth P., 2017/10. Current opinion in biotechnology, 47 pp. 92-101. Peer-reviewed.
 
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant C.L., Szoor A., Torres D., Joseph N., Velasquez M.P., Iwahori K., Gaikwad A., Nguyen P., Arber C., Song X.T. et al., 2016/09/29. Molecular therapy, 24 (9) pp. 1615-1626. Peer-reviewed.
 
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies.
Velasquez M.P., Torres D., Iwahori K., Kakarla S., Arber C., Rodriguez-Cruz T., Szoor A., Bonifant C.L., Gerken C., Cooper L.J. et al., 2016/06/03. Scientific reports, 6 p. 27130. Peer-reviewed.
 
Survivin-specific T cell receptor targets tumor but not T cells.
Arber C., Feng X., Abhyankar H., Romero E., Wu M.F., Heslop H.E., Barth P., Dotti G., Savoldo B., 2015/01. The Journal of clinical investigation, 125 (1) pp. 157-168. Peer-reviewed.
 
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.
Arber C., Abhyankar H., Heslop H.E., Brenner M.K., Liu H., Dotti G., Savoldo B., 2013/09. Gene therapy, 20 (9) pp. 958-962. Peer-reviewed.
 
Mouse models in bone marrow transplantation and adoptive cellular therapy.
Arber C., Brenner M.K., Reddy P., 2013/04. Seminars in hematology, 50 (2) pp. 131-144. Peer-reviewed.
 
Large granular lymphocyte expansion after allogeneic hematopoietic stem cell transplant is associated with a cytomegalovirus reactivation and shows an indolent outcome.
Nann-Rütti S., Tzankov A., Cantoni N., Halter J., Heim D., Tsakiris D., Arber C., Buser A., Gratwohl A., Tichelli A. et al., 2012/11. Biology of blood and marrow transplantation, 18 (11) pp. 1765-1770. Peer-reviewed.
 
Initial cord blood unit volume affects mononuclear cell and CD34+ cell-processing efficiency in a non-linear fashion.
Meyer-Monard S., Tichelli A., Troeger C., Arber C., de Faveri G.N., Gratwohl A., Roosnek E., Surbek D., Chalandon Y., Irion O. et al., 2012/02. Cytotherapy, 14 (2) pp. 215-222. Peer-reviewed.
 
Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT.
Gerull S., Arber C., Bucher C., Buser A., Gratwohl A., Halter J., Heim D., Tichelli A., Stern M., 2011/05. Bone marrow transplantation, 46 (5) pp. 740-746. Peer-reviewed.
 
Graft source determines human hematopoietic progenitor distribution pattern within the CD34(+) compartment.
Arber C., Halter J., Stern M., Rovó A., Gratwohl A., Tichelli A., 2011/05. Bone marrow transplantation, 46 (5) pp. 650-658. Peer-reviewed.
 
High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
O'Meara A., Pabst T., Heim D., Gerull S., Bucher C., Halter J., Arber C., Rovò A., Tichelli A., Gratwohl A. et al., 2011/05. Bone marrow transplantation, 46 (5) pp. 636-640. Peer-reviewed.
 
Black hole in the lung.
Cantoni N., Weisser M., Frei R., Lardinois D., Arber C., 2011/01. Bone marrow transplantation, 46 (1) pp. 154-155. Peer-reviewed.
 
In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
Tzankov A., Strasser U., Dirnhofer S., Menter T., Arber C., Jotterand M., Rovo A., Tichelli A., Stauder R., Günthert U., 2011. Annals of Hematology, 90 (8) pp. 901-909.
 
Hypervariability of biofilm formation and oxacillin resistance in a Staphylococcus epidermidis strain causing persistent severe infection in an immunocompromised patient.
Weisser M., Schoenfelder S.M., Orasch C., Arber C., Gratwohl A., Frei R., Eckart M., Flückiger U., Ziebuhr W., 2010/07. Journal of clinical microbiology, 48 (7) pp. 2407-2412. Peer-reviewed.
 
Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood.
Rovó A., Stüssi G., Meyer-Monard S., Favre G., Tsakiris D., Heim D., Halter J., Arber C., Passweg J., Gratwohl A. et al., 2010/06. International journal of laboratory hematology, 32 (3) pp. 329-335. Peer-reviewed.
 
GATA1 mutations are not a hallmark of acute myeloid leukaemia with t(8;21).
Hoeller S., Bihl M.P., Arber C., Dirnhofer S., Tzankov A., 2010/05. Journal of clinical pathology, 63 (5) pp. 471-472. Peer-reviewed.
 
Double allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies.
Stussi G., Halter J., Tichelli A., Meyer-Monard S., Buser A.S., Arber C., Heim D., Passweg J.R., Rischewski J., Paulussen M. et al., 2010/01. Bone marrow transplantation, 45 (1) pp. 103-109. Peer-reviewed.
 
Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia.
Obermann Ellen Christina, Arber Caroline, Jotterand Martine, Tichelli Andre, Hirschmann Petra, Tzankov Alexandar, 2010. Annals of Hematology, 89 (7) pp. 663-669.
 
Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality.
Cantoni N., Weisser M., Buser A., Arber C., Stern M., Heim D., Halter J., Christen S., Tsakiris D.A., Droll A. et al., 2009/08. European journal of haematology, 83 (2) pp. 130-138. Peer-reviewed.
 
Aplastic anemia and concomitant autoimmune diseases.
Stalder M.P., Rovó A., Halter J., Heim D., Silzle T., Passweg J., Rischewski J., Stern M., Arber C., Buser A. et al., 2009/07. Annals of hematology, 88 (7) pp. 659-665. Peer-reviewed.
 
Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Buser A., Stern M., Arber C., Medinger M., Halter J., Rovo A., Favre G., Lohri A., Tichelli A., Gratwohl A., 2008/10. Bone marrow transplantation, 42 (7) pp. 483-487. Peer-reviewed.
 
Patient and product factors affecting platelet transfusion results.
Heim D., Passweg J., Gregor M., Buser A., Theocharides A., Arber C., Meyer-Monard S., Halter J., Tichelli A., Gratwohl A., 2008/04. Transfusion, 48 (4) pp. 681-687. Peer-reviewed.
 
Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay.
Arber C., Bertrand G., Halter J., Boehlen F., Kaplan C., Gratwohl A., 2007/10. British journal of haematology, 139 (1) pp. 159-161. Peer-reviewed.
 
Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment.
Arber C., Buser A., Heim D., Weisser M., Tyndall A., Tichelli A., Passweg J., Gratwohl A., 2007/09. Bone marrow transplantation, 40 (6) pp. 597-598. Peer-reviewed.
 
Cranial and peripheral neuropathy due to leptomeningeal infiltration in a patient with Waldenstrom's macroglobulinemia.
Sutter R., Arber C., Tichelli A., Steck A.J., Czaplinski A., 2007/08. Journal of neurology, 254 (8) pp. 1122-1123. Peer-reviewed.
 
Visceral leishmaniasis: a threat to immunocompromised patients in non-endemic areas?
Weisser M., Khanlari B., Terracciano L., Arber C., Gratwohl A., Bassetti S., Hatz C., Battegay M., Flückiger U., 2007/08. Clinical microbiology and infection, 13 (8) pp. 751-753. Peer-reviewed.
 
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Buser A.S., Stern M., Bucher C., Arber C., Heim D., Halter J., Meyer-Monard S., Stussi G., Lohri A., Ghielmini M. et al., 2007/03. Bone marrow transplantation, 39 (6) pp. 335-340. Peer-reviewed.
 
Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.
Arber C., Buser A., Heim D., Gratwohl A., Tichelli A., Passweg J.R., 2006/03. European journal of haematology, 76 (3) pp. 255-257. Peer-reviewed.
 
Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation.
Schimmelpfennig C.H., Schulz S., Arber C., Baker J., Tarner I., McBride J., Contag C.H., Negrin R.S., 2005/11. The American journal of pathology, 167 (5) pp. 1321-1331. Peer-reviewed.
 
Protection against lethal Aspergillus fumigatus infection in mice by allogeneic myeloid progenitors is not major histocompatibility complex restricted.
Arber C., Bitmansour A., Shashidhar S., Wang S., Tseng B., Brown J.M., 2005/11/01. The Journal of infectious diseases, 192 (9) pp. 1666-1671. Peer-reviewed.
 
No evidence of plasticity in hair follicles of recipients after allogeneic hematopoietic stem cell transplantation.
Rovó A., Meyer-Monard S., Heim D., Arber C., Passweg J.R., Gratwohl A., Tichelli A., 2005/08. Experimental hematology, 33 (8) pp. 909-911. Peer-reviewed.
 
Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation.
Arber C., BitMansour A., Sparer T.E., Higgins J.P., Mocarski E.S., Weissman I.L., Shizuru J.A., Brown J.M., 2003/07/15. Blood, 102 (2) pp. 421-428. Peer-reviewed.
 
C-reactive protein and fever in neutropenic patients.
Arber C., Passweg J.R., Fluckiger U., Pless M., Gregor M., Tichelli A., Schifferli J.A., Gratwohl A., 2000. Scandinavian journal of infectious diseases, 32 (5) pp. 515-520. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University